BMO Capital starts Globus Medical at Outperform on earnings power
As previously reported, BMO Capital initiated coverage of Globus Medical with an Outperform rating and $94 price target. The market continues to underappreciate the earnings power of the fully integrated platform, the analyst tells investors in a research note. NuVasive synergies are ahead of schedule, Nevro turned accretive faster than expected, and a robotic ecosystem is increasingly driving durable implant pull-through, all underpinned by best-in-class mid-30s EBITDA margins, BMO added.
As previously reported, BMO Capital initiated coverage of Globus Medical with an Outperform rating and $94 price target.
The market continues to underappreciate the earnings power of the fully integrated platform, the analyst tells investors in a research note.
NuVasive synergies are ahead of schedule, Nevro turned accretive faster than expected, and a robotic ecosystem is increasingly driving durable implant pull-through, all underpinned by best-in-class mid-30s EBITDA margins, BMO added.